BioNTech

BioNTech is a global biotechnology company developing next-generation immunotherapies for cancer and other serious diseases. Founded in 2008 by Prof. Ugur Sahin, Prof. Özlem Türeci and Prof. Christoph Huber, the company operates as a fully-integrated business spanning discovery, development and commercialisation, with global sites across those functions. Its stated aim is to translate scientific discovery into treatments, an approach it summarises as "translate science into survival".

The company's portfolio is built around mRNA research and development and extends to cell therapy, antibody-drug conjugates, immunomodulators and CAR-T cell therapies. Its mRNA cancer immunotherapies address disease from early-stage cases with a high risk of recurrence through to advanced and metastatic cancers. BioNTech also developed, in partnership with Pfizer, the first approved mRNA medicinal product for COVID-19. The work draws on deep genomics, artificial intelligence and in-house manufacturing capabilities.

BioNTech's activities sit at the intersection of oncology, infectious disease, immunology and pharmaceuticals, and it operates internationally. The company describes its scientific premise as a belief in the immune system as the fundamental driver of therapeutic success, with an emphasis on research rigour carried through into clinical use.